Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 4Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Breast Neoplasms 315Lymphoma 282Leukemia 227Precursor Cell Lymphoblastic Leukemia-Lymphoma 216Lymphoma, Non-Hodgkin 178Leukemia, Lymphocytic, Chronic, B-Cell 177Multiple Myeloma 174Lymphoma, Large B-Cell, Diffuse 174Lymphoma, Follicular 142Leukemia, Myeloid, Acute 136Lymphoma, Mantle-Cell 126Hodgkin Disease 125Burkitt Lymphoma 118Myelodysplastic Syndromes 110Lymphoma, Large-Cell, Immunoblastic 89Lymphoma, B-Cell, Marginal Zone 85Recurrence 67Neoplasms, Plasma Cell 62Leukemia, Myeloid, Chronic-Phase 59Neuroblastoma 56Dendritic Cell Sarcoma, Interdigitating 56Leukemia, Myeloid, Accelerated Phase 55Myeloproliferative Disorders 54Melanoma 54Congenital Abnormalities 48Neoplasms 47Leukemia, Myelomonocytic, Chronic 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45Blast Crisis 45Lymphoma, Large-Cell, Anaplastic 44

Interventions

Dexamethasone 12Melphalan 7Calcium Dobesilate 6Lenalidomide 5Bortezomib 5Cyclophosphamide 4miridesap 3ixazomib 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2pomalidomide 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Thalidomide 1Tacrolimus 1Pharmaceutical Preparations 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Etanercept 1Drug Evaluation 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Amyloidosis × Cyclophosphamide × Clear all
NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Janssen Research & Development, LLC

Phase 3 Completed
416 enrolled 28 charts 2 FDA
Plasma cell

Amyloidosis

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

NCT00981708 2021-04-30

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

University of Athens

Phase 1/2 Completed
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Recurrence

NCT01194791 2017-04-25

LENDEXAL

PETHEMA Foundation

Phase 2 Completed
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡